News

Published on 1 May 2024 on Zacks via Yahoo Finance

Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates


Article preview image

Pfizer (PFE) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 46.43%. A quarter ago, it was expected that this drugmaker would post a loss of $0.19 per share when it actually produced earnings of $0.10, delivering a surprise of 152.63%.

NASDAQ.SPRB price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates

Pfizer (PFE) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Est...

Zacks via Yahoo Finance 1 May 2024

Novo Holdings sells shares of Spruce Biosciences for $351k By Investing.com

In a recent transaction, Novo Holdings A/S, a significant shareholder in Spruce Biosciences, Inc....

Investing.com 26 Mar 2024

Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why

Spruce Biosciences SPRB stock has declined 86.1% in the past month due to the failure of a key st...

Zacks via Yahoo Finance 24 Mar 2024

Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)

The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. (NASDAQ:SPRB), w...

Simply Wall St. via Yahoo Finance 23 Mar 2024

Novo Holdings A/S unloads over $1.35 million in Spruce Biosciences stock By Investing.com

In a series of transactions this week, Novo Holdings A/S, a significant shareholder in Spruce ...

Investing.com 21 Mar 2024

Novo Holdings sells shares in Spruce Biosciences worth over $1.6 million By Investing.com

Novo Holdings sells shares in Spruce Biosciences worth over $1.6 million

Investing.com 19 Mar 2024

Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price

Spruce Biosciences, Inc. (NASDAQ:SPRB) investors will be delighted, with the company turning in s...

Simply Wall St. via Yahoo Finance 16 Mar 2024

Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall Spruce Biosciences'...

Spruce Biosciences Inc SPRB shares plummeted on Thursday after the company released topline resul...

Benzinga 14 Mar 2024

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In...

Shares of Limbach Holdings, Inc. LMB fell sharply during Thursday’s session after the company re...

Benzinga 14 Mar 2024

Spruce Biosciences stock target cut to $3 on trial compliance issues By Investing.com

Spruce Biosciences stock target cut to $3 on trial compliance issues

Investing.com 14 Mar 2024